New trials, publications, preprints and grants on this target, month by month.
Trial
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
4 Jan 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
31 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Primary anorectal melanoma with BRAF V600 wild-type status presenting with widespread metastases in a 29-year-old man: a case report.
4 Nov 2026· Journal of surgical case reports· PUBMED
Publication
ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials.
30 Oct 2026· Journal of gastrointestinal cancer· PUBMED
Publication
Targeted BRAF /MEK inhibition as a salvage therapy for patients with metastatic melanoma harboring a BRAF L597R mutation: two case reports and review of the literature.
28 Oct 2026· Melanoma research· PUBMED
Publication
Treatment discontinuation after complete response to BRAF/MEK inhibition in metastatic melanoma: long-term clinical outcomes from a single institution.
28 Oct 2026· Melanoma research· PUBMED
Publication
Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.
28 Oct 2026· Annals of hematology· PUBMED
Publication
Beyond BRAF V600: emerging MAPK-targeted therapeutic strategies.
23 Oct 2026· Annals of translational medicine· PUBMED
Publication
Multimodal treatment of isolated leptomeningeal relapse in BRAF-mutated dMMR colon cancer.
23 Oct 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
Cytotoxic activity of selinexor in BRAFV600E-driven pediatric low-grade glioma 3D cultures.
22 Oct 2026· Acta neuropathologica communications· PUBMED
Publication
BRAF-Targeted Anticancer Agents: Synthesis, Molecular Docking, and In Vitro Evaluation of Novel 1,3,4-Thiadiazolyl-Benzamide Derivatives.
22 Oct 2026· Current drug discovery technologies· PUBMED
Trial
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
20 Oct 2026· NA · RECRUITING· CTGOV
Publication
Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma.
20 Oct 2026· Experimental hematology & oncology· PUBMED
Publication
Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study.
20 Oct 2026· Combinatorial chemistry & high throughput screening· PUBMED
Publication
Deep learning techniques in predicting BRAF mutation status in cutaneous melanoma from histopathologic images.
18 Oct 2026· Journal of clinical pathology· PUBMED
Publication
From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma.
17 Oct 2026· American journal of clinical dermatology· PUBMED
Publication
Pharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma.
16 Oct 2026· Disease models & mechanisms· PUBMED
Publication
Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.
16 Oct 2026· JCO precision oncology· PUBMED
Publication
[Patients with papillary craniopharyngioma successfully treated with BRAF and MEK inhibitors].
16 Oct 2026· Lakartidningen· PUBMED
Publication
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.
15 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Quantitative systems pharmacology modeling of class I-III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design.
13 Oct 2026· iScience· PUBMED
Publication
Prevalence and Diagnostic Performance of the BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Cross-Sectional Study in Uruguay.
12 Oct 2026· Acta cytologica· PUBMED
Publication
Diagnostic Accuracy of VE1 Immunohistochemistry for BRAF p.V600E in Colorectal Carcinoma: A Systematic Review.
12 Oct 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up.
8 Oct 2026· Frontiers in endocrinology· PUBMED
Publication
The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
8 Oct 2026· Leukemia research reports· PUBMED
Publication
Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.
2 Oct 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.
2 Oct 2026· JCO precision oncology· PUBMED
Publication
Correction: BRAFV600E-Driven Lung Adenocarcinoma Requires Copper to Sustain Autophagic Signaling and Processing.
2 Oct 2026· Molecular cancer research : MCR· PUBMED
Trial
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
1 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV